HCG horionicheskiy

When ATH:
G03GA01

Characteristic.

Vodorastvorimыy glycoprotein, produced by the placenta and obtained from the urine of pregnant women. White or almost white sterile lyophilized powder; stable; as a solution tinctures.

Pharmacological action.
Gonadotrophic, luteinizing.

Application.

Hypogonadal when the hypothalamic-pituitary disorders: у женщин — бесплодие, due to pituitary-ovarian dysfunction, incl. after pre-stimulation of follicular maturation and proliferation of the endometrium, violation, including lack of, menstrual cycle, dysfunctional uterine bleeding of childbearing age, failure of function of the corpus luteum, habitual and threatening miscarriage in I trimester of pregnancy, controlled "superovulation" for artificial insemination; у мужчин — гипогонадотропный гипогонадизм, phenomenon evnuhoidizma, gipogenitalizma, hypoplasia of the testes, adiposogenital syndrome, disorders of spermatogenesis (oligospermatism, azoospermia), cryptorchism.

Contraindications.

Hypersensitivity, incl. to others. gonadotropinam, hypertrophy or a tumor of the pituitary gland, gormonalnozavisimyh tumors or inflammatory diseases of the genital organs, cardiac and renal failure, bronchial asthma, epilepsy, migraine; у женщин — синдром гиперстимуляции яичников или его угроза, undiagnosed dysfunctional uterine bleeding, uterine fibroma, ovarian cysts or hypertrophy, not related to his polycystic, thrombosis in the acute stage; у мужчин — рак предстательной железы, adrenarche (for the treatment of cryptorchidism).

Restrictions apply.

Polycystic ovaries (for ovulation induction), Children up to age 4 years (Safety and efficacy have not determined).

Pregnancy and breast-feeding.

During pregnancy should take into account the likelihood of adverse effects on the fetus (according to, obtained when administered to pregnant women and experimental animals).

Side effects.

From the nervous system and sensory organs: headache, irritability, anxiety, fatiguability, weakness, depression.

Allergic reactions: rash (such as urticaria, эritematoznaya), angioedema, dyspnoea.

Other: antibody formation (prolonged use), breast enlargement, pain at the injection site.

With the genitourinary system: у женщин — гипертрофия яичников, the formation of ovarian cysts, ovarian hyperstimulation syndrome, polycyesis, peripheral edema; у мужчин — преждевременное половое созревание, enlargement of the testicles in the inguinal canal, obstructing their further lowering, degeneration of the gonads, atrophy of the seminiferous tubules.

Cooperation.

Combined with menotropinami urofollitropinom and increases the likelihood of pregnancy and preterm delivery, the severity of ovarian hyperstimulation syndrome.

Overdose.

У женщин при индукции овуляции — острый синдром гиперстимуляции яичников (may occur spontaneously at the beginning of menstruation). Symptoms: sharp pain in the abdomen (especially in the groin), nausea, vomiting, diarrhea, flatulence, decrease in urine output, hurried breathing, edema of the lower extremities, в тяжелых случаях — гиповолемия, blood clots, electrolyte imbalance, ascites, peritonitis, gidrotoraks, Acute pulmonary insufficiency, thromboembolic events.

Treatment: the temporary removal of the drug, при необходимости — госпитализация, appointment of symptomatic therapy to correct water-salt balance, clotting, etc.. violations.

Dosing and Administration.

/ M. Женщинам — for the induction of ovulation and the use of methods of artificial insemination: по 5000–10000 МЕ через день после последнего введения менотропинов или урофоллитропина либо через 5–9 дней после последнего введения кломифена; at the failure of the corpus luteum - By 1500 МЕ каждые вторые сутки, starting from the day of ovulation until the day of expected menstruation or pregnancy confirmation (in the latter case it is possible to re-use 10 weeks of pregnancy). Мужчинам — hypogonadotropic hypogonadism when по 1000–4000 МЕ 2–3 раза в неделю в течение нескольких недель или месяцев либо до получения терапевтического эффекта; for the induction of spermatogenesis in infertility during 6 months or more; if the number of sperm in the ejaculate is inadequate (less 5 млн/мл) or complementary treatments menotropinami urofollitropinom and continue for another 12 Months. In prepubertal cryptorchidism — по 1000–5000 МЕ 2–3 раза в неделю до получения желаемого эффекта, but not more 10 doses; диагностика гипогонадизма у юношей — по 2000 ME 1 once a day for 3 days.

Precautions.

Treatment is carried out under the supervision of a qualified physician, with experience in treatment of endocrine disorders. When used for ovulation induction recommended dosing regimen individual choice and its correction depending on the efficiency, regular measurement of estradiol and progesterone concentrations in serum, Ultrasound of the ovaries, daily basal body temperature determination and respect for the sex life, recommended by your doctor. The development of hypertrophy or formation of ovarian cysts require temporary discontinuation of treatment (To avoid tearing the cyst), abstaining from sexual intercourse and to reduce the dose for the next course. When large ovarian hypertrophy, or excessive increase in the concentration of estradiol in the blood serum of the last day of treatment or menotropinami urofollitropinom induction of ovulation in the cycle is not carried out. During treatment of male sterility is necessary to measure the concentration of testosterone in serum before and after administration, determine the number and mobility of sperm. When precocious puberty during treatment cryptorchidism therapy canceled and use etc.. Treatments. In the absence of testicular descent dynamics after administration 10 doses of continued treatment is not recommended. Diagnosis of hypogonadism in young men is performed under the control of the concentration of testosterone in the blood serum before the introduction of and the day after treatment (in normal testicular function after treatment concentration should increase 2 times). Unreasonable increase in dose or duration of use may be accompanied by a decrease in the number of sperm in the ejaculate in men.

Cautions.

The solutions were prepared immediately before use in the isotonic sodium chloride solution. It should take into account the likelihood of false positives immunoassay for the maintenance of endogenous hCG and the possibility of increasing the concentration of 17-gidroksikortikosteroidov and 17-ketosteroids in urine.

Cooperation